<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01423773</url>
  </required_header>
  <id_info>
    <org_study_id>P-367-C-800</org_study_id>
    <nct_id>NCT01423773</nct_id>
  </id_info>
  <brief_title>Ocular Comfort and OCT Observation of Post Lens Clearance and Ocular Tissue Compression</brief_title>
  <official_title>Ocular Comfort and OCT Observation of Post Lens Clearance and Ocular Tissue Compression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CIBA VISION</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bascom Palmer Eye Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Alcon Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to compare the fit and comfort of two types of contact lenses.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The relationship between ocular comfort and the Optical Coherence Tomography (OCT)
      measurements of post lens clearance and ocular tissue compression was studied.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Final Comfort</measure>
    <time_frame>Day 2, Hour 10</time_frame>
    <description>Comfort was assessed by the participant on a Visual Analog Scale of 0 to 100, where 0=Extremely Uncomfortable (&quot;My eyes are in pain. I cannot tolerate my lenses&quot;) and 100=Extremely Comfortable (&quot;My eyes feel GREAT, better than normal. I cannot feel my lenses&quot;).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Ocular Comfort</condition>
  <arm_group>
    <arm_group_label>Lotrafilcon A test/lotrafilcon A control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Lotrafilcon A test contact lens worn first, with lotrafilcon A control contact lens worn second. Each product worn bilaterally for two days as follows: 20 minutes on Day 1 and 10 hours on Day 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lotrafilcon A control/lotrafilcon A test</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Lotrafilcon A control contact lens worn first, with lotrafilcon A test contact lens worn second. Each product worn bilaterally for two days as follows: 20 minutes on Day 1 and 10 hours on Day 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Lotrafilcon A test contact lens</intervention_name>
    <description>Silicone hydrogel single vision, soft contact lens with alternate parameters</description>
    <arm_group_label>Lotrafilcon A test/lotrafilcon A control</arm_group_label>
    <arm_group_label>Lotrafilcon A control/lotrafilcon A test</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Lotrafilcon A control contact lens</intervention_name>
    <description>Silicone hydrogel single vision, soft contact lens</description>
    <arm_group_label>Lotrafilcon A test/lotrafilcon A control</arm_group_label>
    <arm_group_label>Lotrafilcon A control/lotrafilcon A test</arm_group_label>
    <other_name>Night&amp;Day</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ultra-High Resolution Optical Coherence Tomographer (OCT)</intervention_name>
    <description>Investigational, nonsignificant risk device for measuring post lens clearance and ocular tissue compression during contact lens wear</description>
    <arm_group_label>Lotrafilcon A test/lotrafilcon A control</arm_group_label>
    <arm_group_label>Lotrafilcon A control/lotrafilcon A test</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Be of legal age of consent and sign Informed Consent document.

          -  Normal binocularity.

          -  Be able to wear soft contact lenses.

          -  Willing to comply with the wear and study visit schedule.

          -  Spherical contact lens prescription within 0.50 diopter of the available lens powers.

          -  Spectacle cylinder less than or equal to 1.50 diopter.

          -  Other protocol-defined inclusion criteria may apply.

        Exclusion Criteria:

          -  Eye injury or surgery within twelve weeks of enrollment.

          -  Pre-existing ocular irritation that would preclude contact lens fitting.

          -  Currently enrolled in any clinical trial.

          -  Evidence of systemic or ocular abnormality, infection, or disease likely to affect
             successful wear of contact lenses or use of accessory solutions as determined by the
             investigator.

          -  Other protocol-defined exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jianhua Wang, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bascom Palmer Eye Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>McKnight Building, Bascom Palmer Eye Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 25, 2011</study_first_submitted>
  <study_first_submitted_qc>August 25, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2011</study_first_posted>
  <results_first_submitted>November 21, 2012</results_first_submitted>
  <results_first_submitted_qc>November 21, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 21, 2012</results_first_posted>
  <last_update_submitted>June 20, 2013</last_update_submitted>
  <last_update_submitted_qc>June 20, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 28, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Partipants were recruited from one US study center.</recruitment_details>
      <pre_assignment_details>This reporting group includes all enrolled participants.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Lotrafilcon A Test, Then Lotrafilcon A Control</title>
          <description>Lotrafilcon A test contact lenses worn in Period One, with lotrafilcon A control contact lenses worn in Period Two. Each product was worn bilaterally for two consecutive days as follows: 20 minutes on Day 1, and 10 hours on Day 2. A wash-out of 24 hours minimum to 3 weeks maximum separated the two periods.</description>
        </group>
        <group group_id="P2">
          <title>Lotrafilcon A Control, Then Lotrafilcon A Test</title>
          <description>Lotrafilcon A control contact lenses worn in Period One, with lotrafilcon A test contact lenses worn in Period Two. Each product was worn bilaterally for two consecutive days as follows: 20 minutes on Day 1, and 10 hours on Day 2. A wash-out of 24 hours minimum to 3 weeks maximum separated the two periods.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period One, 2 Days</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 2, 2 Days</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Overall</title>
          <description>Each product worn bilaterally for two consecutive days in either Period One or Period Two. A wash-out of 24 hours minimum to 3 weeks maximum separated the two periods.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.0" spread="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Final Comfort</title>
        <description>Comfort was assessed by the participant on a Visual Analog Scale of 0 to 100, where 0=Extremely Uncomfortable (&quot;My eyes are in pain. I cannot tolerate my lenses&quot;) and 100=Extremely Comfortable (&quot;My eyes feel GREAT, better than normal. I cannot feel my lenses&quot;).</description>
        <time_frame>Day 2, Hour 10</time_frame>
        <population>All enrolled participants</population>
        <group_list>
          <group group_id="O1">
            <title>Lotrafilcon A Test</title>
            <description>Lotrafilcon A test contact lenses worn for two consecutive days as follows: 20 minutes on Day 1, and 10 hours on Day 2.</description>
          </group>
          <group group_id="O2">
            <title>Lotrafilcon A Control</title>
            <description>Lotrafilcon A control contact lenses worn for two consecutive days as follows: 20 minutes on Day 1, and 10 hours on Day 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Final Comfort</title>
          <description>Comfort was assessed by the participant on a Visual Analog Scale of 0 to 100, where 0=Extremely Uncomfortable (&quot;My eyes are in pain. I cannot tolerate my lenses&quot;) and 100=Extremely Comfortable (&quot;My eyes feel GREAT, better than normal. I cannot feel my lenses&quot;).</description>
          <population>All enrolled participants</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.6" spread="10.5"/>
                    <measurement group_id="O2" value="87.9" spread="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected for the duration of the study.</time_frame>
      <desc>This reporting group includes all enrolled participants.</desc>
      <group_list>
        <group group_id="E1">
          <title>Lotrafilcon A Test</title>
          <description>Lotrafilcon A test contact lenses worn for two consecutive days as follows: 20 minutes on Day 1, and 10 hours on Day 2.</description>
        </group>
        <group group_id="E2">
          <title>Lotrafilcon A Control</title>
          <description>Lotrafilcon A control contact lenses worn for two consecutive days as follows: 20 minutes on Day 1, and 10 hours on Day 2.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The sample size may be small for establishing relationship between ocular comfort and other measurable variables.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Head, Clinical Trial Management</name_or_title>
      <organization>Alcon Research</organization>
      <phone>1-800-241-7629</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

